Publication | Closed Access

Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes

Clinical CourseCancer ImmunosurveillanceAutoimmune DiseaseCancer TreatedMedicineThyroid DiseaseImmunologyImmune Checkpoint InhibitorAutoimmunityThyroid HormoneImmunotherapyOncologyRadiation Oncology